Two studies indicated that the SARS-CoV-2 vaccines from Pfizer-BioNTech and Moderna have lower neutralizing antibody responses to the B.1.351 viral lineage, according to the Washington Post.
The AP reports that a bill introduced to the US House of Representatives would provide $1.75 billion to sequence SARS-CoV-2 samples to spot viral changes.